Allogeneic Hematopoietic Cell Transplantation Versus Drugs in Myelofibrosis: The Risk-Benefit Balancing Act

Bone Marrow Transplantation - United Kingdom
doi 10.1038/bmt.2009.193
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation

Haematologica
Hematology
2016English

Infectious Risk After Allogeneic Hematopoietic Cell Transplantation Complicated by Acute Graft-Versus-Host Disease

Biology of Blood and Marrow Transplantation
TransplantationHematology
2017English

Allogeneic Hematopoietic Stem Cell Transplantation

Archives of Internal Medicine
2002English

Allogeneic Stem Cell Transplantation as Treatment for Myelofibrosis

Bone Marrow Transplantation
TransplantationHematology
2006English

Pulmonary Tuberculosis in Allogeneic Hematopoietic Stem Cell Transplantation

Bone Marrow Transplantation
TransplantationHematology
2001English

Allogeneic Hematopoietic Stem Cell Transplantation for Intermediate Cytogenetic Risk AML in First CR

Bone Marrow Transplantation
TransplantationHematology
2012English

Second Allogeneic Hematopoietic Cell Transplantation Versus Donor Cellular Infusion for Relapse After Transplant

Biology of Blood and Marrow Transplantation
TransplantationHematology
2015English

Allogeneic Transplantation for Myelofibrosis With Adverse Risk Karyotype: Attack on the Clones?

American Journal of Hematology
Hematology
2018English

Toll-Like Receptor Polymorphisms in Allogeneic Hematopoietic Cell Transplantation

Biology of Blood and Marrow Transplantation
TransplantationHematology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy